EUVIMEDEUVIMED entdecken
Crossref

Controversies and current practices in CNS relapse of diffuse large B-cell lymphoma

Robert Puckrin, Douglas A. Stewart

Canadian Hematology Today · 2022

DOI: 10.58931/cht.2023.2122 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Canadian Hematology Today, 2022. Verfasst von Robert Puckrin und 1 weiteren Autor:innen. Die Arbeit nennt 40 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Central nervous system (CNS) relapse is an uncommon complication of diffuse large B-cell lymphoma (DLBCL), occurring in approximately 3–5% of patients and at a median timepoint of 6–9 months from diagnosis. Approximately half of these cases present as isolated CNS relapse caused by occult seeding of the CNS early in the disease course, while the remaining cases occur in the context of concurrent systemic relapse. The median survival after CNS relapse is only 4–6 months, highlighting the unmet need to identify effective prophylaxis and management strategies. This article provides an overview of current controversies and optimal strategies for prognosticating, preventing, and treating CNS relapse in patients with DLBCL.

Zitieren

APA

Puckrin, R., & Stewart, D. A. (2022). Controversies and current practices in CNS relapse of diffuse large B-cell lymphoma. Canadian Hematology Today. https://doi.org/10.58931/cht.2023.2122

Vancouver

Puckrin R, Stewart DA. Controversies and current practices in CNS relapse of diffuse large B-cell lymphoma. Canadian Hematology Today. 2022. doi:10.58931/cht.2023.2122

BibTeX
@article{Puckrin2022,
  author = {Puckrin, Robert and Stewart, Douglas A.},
  title = {Controversies and current practices in CNS relapse of diffuse large B-cell lymphoma},
  journal = {Canadian Hematology Today},
  year = {2022},
  doi = {10.58931/cht.2023.2122}
}
Kostenlos starten →